Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cancer Res ; 22(1): 70-81, 2024 Jan 02.
Article in English | MEDLINE | ID: mdl-37768171

ABSTRACT

Pseudomyxoma peritonei (PMP) is a rare malignant clinical syndrome with little known about the global mutation profile. In this study, whole-exome sequencing (WES) was performed in 49 appendiceal PMP to investigate mutation profiles and mutation signatures. A total of 4,020 somatic mutations were detected, with a median mutation number of 56 (1-402). Tumor mutation burden (TMB) was generally low (median 1.55 mutations/Mb, 0.12-11.26 mutations/Mb). Mutations were mainly enriched in the function of cancer-related axonogenesis, extracellular matrix-related processes, calcium signaling pathway, and cAMP signaling pathway. Mutations in FCGBP, RBFOX1, SPEG, RTK-RAS, PI3K-AKT, and focal adhesion pathways were associated with high-grade mucinous carcinoma peritonei. These findings revealed distinct mutation profile in appendiceal PMP. Ten mutation signatures were identified, dividing patients into mutation signature cluster (MSC) 1 (N = 28, 57.1%) and MSC 2 (N = 21, 42.9%) groups. MSC (P = 0.007) was one of the four independent factors associated with 3-year survival. TMB (P = 0.003) and microsatellite instability (P = 0.002) were independent factors associated with MSC 2 grouping. Taken together, our findings provided a broader view in the understanding of molecular pathologic mechanism in appendiceal PMP and may be critical to developing an individualized approach to appendiceal PMP treatment. IMPLICATIONS: This work describes exhaustive mutation profile of PMP based on WES data and derives ten mutation signatures, which divides patients into two clusters and serve as an independent prognostic factor associated with 3-year survival.


Subject(s)
Peritoneal Neoplasms , Pseudomyxoma Peritonei , Humans , Pseudomyxoma Peritonei/genetics , Pseudomyxoma Peritonei/pathology , Peritoneal Neoplasms/genetics , Peritoneal Neoplasms/pathology , Exome Sequencing , Phosphatidylinositol 3-Kinases/genetics , Mutation , Biomarkers, Tumor/genetics
2.
Environ Sci Pollut Res Int ; 30(11): 30727-30740, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36441310

ABSTRACT

The Yangtze River Economic Belt, an inland economic zone with global influence, has shown a trend of prosperous economic development in recent years. Economic development, water pollution, resource depletion, and other environmental problems continue to emerge. The steady state of the water ecological environment is an important aspect of ecological security. To investigate the regional water ecological security state, this study constructs a comprehensive evaluation indicator system within the framework of "driving force-carrying source-state-management" (DCSM). The entropy weight method was used to determine the weight of each indicator, and the weighted rank sum ratio model was introduced to classify the water ecological environment of the Yangtze River Economic Belt from 2010 to 2019. Finally, an adversarial interpretative structure model is used to refine the ranking of each region. The results show that the bearing state and driving force subsystems are closely related to the water ecological environment. The top three indicators are wastewater discharge of industrial added value of 10,000 yuan, water consumption per 10,000 yuan of industrial gross product, and water consumption per 10,000 yuan of tertiary gross domestic product. In addition, there are clear differences in the water ecological environment of the Yangtze River Economic Belt. The classification results show that Zhejiang and Jiangsu are rated as "excellent''; Yunnan, Guizhou, Anhui, and Jiangxi are in the "good" level; and Sichuan, Hunan, Chongqing, and Hubei are in the "medium" level. Shanghai is "poor." As a whole, the downstream is superior, the upstream is second, and the midstream is poor in an asymmetric "U"-shaped distribution. During the study period, the overall state of water ecology in the Yangtze River Economic Belt was at a medium level and has not yet reached a safe and steady state. The performance of areas with traditional industrialization as the main development path was poor. Therefore, it is necessary to pay attention to the overall water ecological security in the basin in the future, strengthen the regulatory role of the government's water ecological management, promote reform of traditional industries and resource-based regions, and achieve the sustainable development of the water ecological environment.


Subject(s)
Economic Development , Industrial Development , China , Sustainable Development , Industry , Cities
3.
Respirol Case Rep ; 10(11): e01054, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36258694

ABSTRACT

Acquired resistance to osimertinib is inevitable and heterogeneous despite its documented efficacy against EGFR-mutated non-small cell lung cancer (NSCLC). Subsequent therapeutic options assume the dominant form of the resistance mechanism; however, the more rare oncogenic driver, NTRK1 fusion, has also reportedly conferred osimertinib resistance. Nevertheless, clear-cut options when NSCLCs are driven by EGFR mutation and the subsequent NTRK fusion are lacking. This is a case of NSCLC wherein exon 19 deletion in EGFR (19del) and acquired LMNA-NTRK1 fusion were accompanied by the persistence of EGFR T790M. The patient underwent peritoneal metastasis after multiple targeted therapies: gefitinib, osimertinib, chemotherapy, and anlotinib plus docetaxel (in clinical trials). Osimertinib was subsequently re-administered with the NTRK fusion inhibitor entrectinib, resulting in remission of peritoneal metastases even after slow progression of pancreatic metastasis over the following 5 months. An extensive literature review to identify the efficacies of therapies for NTRK fusion as the means to acquired resistance to EGFR TKIs revealed that blocking both the EGFR mutation and the subsequent NTRK fusion can provide clinical benefits following EGFR TKIs resistance; however, the efficacy and safety of combination therapies must be further investigated. To precisely manage EGFR-mutated NSCLCs, it is also essential to identify the resistance mechanisms by repeating biopsies.

4.
J Gene Med ; 24(6): e3420, 2022 06.
Article in English | MEDLINE | ID: mdl-35470535

ABSTRACT

BACKGROUND: The present study aimed to explore the genomic profile in a cohort of Chinese patients with breast cancer (BC), as well as provide potential strategies for clinic treatment in specific subset of BC patients. METHODS: Paired samples from 46 BC patients were subjected to DNA extraction and 537 gene targeted next-generation sequencing. RESULTS: In total, 742 somatic mutations were detected in these patients, which involved 303 genes. TP53 and PIK3CA were the most frequently mutated genes, with a mutation rate of 45.65% and 26.09%. C>T, T>C and C>A comprised the main single nucleotide base variation for this Chinese cohort. Triple negative breast cancer (TNBC) group had more TP53-mutated patients than the Non-TNBC group (p = 0.0229). In addition, the cohort was also divided into 'Young' and 'Old' groups based on the age of onset. Compared with the 'Young' group, the 'Old' group had more frameshift mutations (p = 0.0190), less missense mutations (p = 0.0269) and more HOXA11-mutated patients (p = 0.0197). Additionally, the HOXA11mt (HOXA11 gene mutated) group had more frameshift mutations than the HOXA11wt (HOXA11 gene without mutation) group (p < 0.0001). In KEGG (i.e. Kyoto Encyclopedia of Genes and Genomes) analysis, the HOXA11wt group had more gene mutations involved in the T cell receptor signaling pathway (p = 0.0197), Jak-STAT signaling pathway (p = 0.0380) and the HIF-1 signaling pathway (p = 0.0489) than the HOXA11mt group. In the present study, the heterogeneity of somatic mutations was revealed between different tumor subgroups, including TNBC/Non-TNBC, age of onset (Young/Old) and HOXA11 mutation (HOXA11mt /HOXA11wt ). CONCLUSIONS: The present study revealed the heterogeneity of gene mutation and clinical variables among BC subtypes and might provide guidance for developing a potential target for clinical treatment.


Subject(s)
Breast Neoplasms , Triple Negative Breast Neoplasms , Breast Neoplasms/genetics , Breast Neoplasms/pathology , China , Female , Genomics , High-Throughput Nucleotide Sequencing , Humans , Mutation , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...